

Clinical Specialty Infusions, LLC

Phone: 833-569-1005 | Fax: 430-200-4889 | Online: deliver.myforcura.com

REMICADE/ENTYVIO/STELARA ENROLLMENT FORM

Account manager:	Contact info:

			DATIENT INFO	DRAATION!		· <u>·</u>				
PATIENT INFORMATION										
Patient Name:			Patient/Caregiver (if applicable):							
Address:			City:			State: Zip:		Zip:		
Main phone: Alterna		Alternate phone:	Email:			Last 4 of SSN (required):				
Date of birth:		☐ Male or ☐ Female	Height (required)	: 🔲 cm or	inches	Weight (requir	ed):	☐ Ib or ☐ kg		
			CLINICAL INFO	RMATION						
Primary ICD-10 code: Is patient currently on therapy? ☐ Yes or ☐ No Previous tried/failed therapies:										
Allergies: Current medications:										
Please include face sheet, copy of insurance cards (front and back), H&P, clinicals, and any available lab results.										
PRESCRIPTION AND ORDERS										
Medication	Dosing				Quantity			Refills		
☐ Entyvio	Induction:		Maintenance:			3 doses for induction		x1 year unless		
	300mg IV at 0		☐ 300mg IV every 8 weeks after induction			ek supply for maintenance		otherwise noted:		
	Other:		Other:		Other: _			week supply		
☐ Infliximab	Induction:		Maintenance:		□ 2 doso f	or industion		Other: xx1 year unless		
(Remicade, Smg/kg IV at Conflectra, Other:		0, 2 & 6 weeks	mg/kg IV every 8 weeks after induction			dose for induction -week supply for maintenance ther:		otherwise noted:		
								week supply		
Renflexis,			Other:		_	_		Other: x		
Avsola*)	•	elect infliximab product unles	. ,	ed. Preferred bra						
Simponi Aria	Induction: Adults: 2mg/kg IV at weeks 0 & 4		Maintenance: Adults: 2mg/kg IV every 8 weeks after			2 doses for induction 8-week supply for maintenance		x1 year unless otherwise noted:		
		No five at weeks o at 1	induction Other:			Other:		week supply		
								Other: x		
		5kg: 260mg IV at week 0 5kg-85kg: 390mg IV at week 0	Maintenance (adults):	after industion		se for induction supply for main	tononco	☐ No refills ☐ Other: x		
Crohn's disease / ulcerative colitis		5kg: 520mg IV at week 0	Other:	s after induction	□ 8-меек	supply for main	tenance	Other: x		
☐ Stelara	Induction:	0 0	Maintenance:		One dos	e for induction		☐ No refills		
		g: 45mg SC at weeks 0 & 4				supply for mai	ntenance	Other: x		
and psoriatic arthritis		g: 90mg SC at weeks 0 & 4	Adults >100kg: 90mg So							
Orders:			Other.		-					
Clinical Pharm	acist to dose and	send orders for review/signate	ture. Labs:							
_		loride 0.9% 5-10mL and Hepa		needed for catheter i	maintenance.					
		es, including ambulatory infus								
Pre-Treatment:		0. 500 1000 15 20	:+-:-f:			tic Reactions, p	er protoc	ol:		
		O: 500-1000mg, 15-30 min pr PO: 500-1000mg, 15-30 min p				000, 1 mL x 2 ne 25mg tab #2				
☐ Hydration: Sodium chloride 0.9% 100-500 mL IV over 30 min before each infusion, as needed ◆ Sodium chloride 0.9% 1000 mL Bag #1										
Diphenhydramine 50mg/1mL vial #1 Nursing Orders for Home Infusion: MONITOR (IV only)										
Observe: Vital signs prior to infusion. Blood pressure and pulse every 15 minutes for first hour, then every 30 minutes until stable infusion rate, then every hour. Watch for:										
Signs of fluid overload, cardiovascular symptoms, allergic reaction							Other:			
PRN: Ondansetron 4mg slow IVP as pre-med for infusion induce Toradol 15mg-30mg SIVP as pre-med for infusion induce						-	J Other.			
_		/kg (12.5-125 mg) slow IVP as	•		s reaction or h	neadache				
Ondanse	etron 4-8mg PO a	s pre-med, then every	hours x post-infusion	1						
			PRESCRIPTION AI	ND ORDERS						
Physician name:				Practice site name:						
Address:				City:		State:		Zip:		
NPI:		Phon	e:		Fax:					
Office contact and special instructions:										
Prescriber Authorization: I authorize the pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient										
data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.										
Prescriber's signature: Date:										